Low lean tissue mass is an independent risk factor for mortality in patients with stages 4 and 5 non-dialysis chronic kidney disease

Almudena Vega, Soraya Abad, Nicolás Macías, Inés Aragoncillo, Alba Santos, Isabel Galán, Santiago Cedeño, Juan Manuel López-Gómez, Almudena Vega, Soraya Abad, Nicolás Macías, Inés Aragoncillo, Alba Santos, Isabel Galán, Santiago Cedeño, Juan Manuel López-Gómez

Abstract

Background: Mortality in patients with stages 4 and 5 chronic kidney disease (CKD) is higher than in the general population. Body composition predicts mortality. Our objective was to evaluate the effect of body composition on mortality in patients with stages 4 and 5 non-dialysis CKD. Methods: We performed a prospective study of 356 patients with stages 4 and 5 non-dialysis CKD. At baseline, we recorded general characteristics, history of cardiovascular events, body composition, serum inflammatory markers, nutrition and cardiac biomarkers. Body composition was analysed using bioimpedance spectroscopy. We recorded the lean tissue index (LTI), fat tissue index (FTI) and overhydration (OH). During a median (range) follow-up of 22 (3-49) months, we recorded mortality, cardiovascular events and progress to renal replacement therapy. Results: At baseline, mean (± standard deviation) age was 67 ± 13 years (men 64%; diabetes 36%). Mean body mass index was 28.2 ± 12.8 kg/m2, the FTI was 12.3 ± 5.6 kg/m2, the LTI was 15.7 ± 3.4 kg/m2 and median (interquartile range) OH was 0.6 (-0.4 to 1.5) L. Sixty-four (18%) patients died during follow-up. The univariate Cox analysis showed an association between mortality and age, low LTI, high Charlson comorbidity index, previous cardiovascular events, OH, low albumin and prealbumin levels, and high C-reactive protein levels. Kaplan-Meier analysis revealed higher survival in patients with a higher LTI (log-rank, 9.47; P = 0.002). The multivariate Cox analysis confirmed an association between mortality and low LTI (P = 0.031), previous cardiovascular events (P = 0.003) and high Charlson comorbidity index (P = 0.01). We did not find any association between body composition and cardiovascular events or renal replacement therapy. Conclusions: A low LTI is an independent factor for mortality in patients with stages 4 and 5 CKD.

Keywords: bioimpedance; body mass index; chronic renal failure; nutrition; survival.

Figures

Fig. 1
Fig. 1
Comparative survival between patients with high (green line) versus low (blue line) LTI (Kaplan–Meier plot).
Fig. 2
Fig. 2
Comparative survival between patients with high (green line) versus low (blue line) LTI (Cox plot, Charlson comorbidity index and previous cardiovascular events have been included).

References

    1. Mariani L, Stengel B, Combe C. et al. The CKD outcomes and practice patterns study (CKDopps): rationale and methods. Am J Kidney Dis 2016; 68: 402–413
    1. Sumida K, Molnar MZ, Potukuchi PK. et al. Association of slopes of estimated glomerular filtration rate with post-end-stage renal disease mortality in patients with advanced chronic kidney disease transitioning to dialysis. Mayo Clin Proc 2016; 91: 196–207
    1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2013; 3: S1–S150
    1. Bover J, Ureña P, Ruiz-García C. et al. Clinical and practical use of calcimimetics in dialysis patients with secondary hyperparathyroidism. Clin J Am Soc Nephrol 2016; 11: 161–174
    1. Tsai YC, Chiu YW, Tsai JC. et al. Association of fluid overload with cardiovascular morbidity and all-cause mortality in stages 4 and 5 CKD. Clin J Am Soc Nephrol 2015; 10: 39–46
    1. Yuan J, Watanabe M, Suliman M. et al. Serum hepatocyte growth factor is associated with truncal fat mass and increased mortality in chronic kidney disease stage 5 patients with protein-energy wasting. Nephrol Dial Transplant 2015; 30: 274–282
    1. Zoccali C, Torino C, Tripepi G. et al. Assessment of obesity in chronic kidney disease: what is the best measure? Curr Opin Nephrol Hypertens 2012; 21: 641–646
    1. Caetano C, Valente A, Oliveira T. et al. Body composition and mortality predictors in hemodialysis patients. J Ren Nutr 2016; 26: 81–86
    1. Park J, Ahmadi SF, Streja E. et al. Obesity paradox in end-stage kidney disease patients. Prog Cardiovasc Dis 2014; 56: 415–425
    1. Kalantar-Zadeh K, Abbott KC, Salahudeen AK. et al. Survival advantages of obesity in dialysis patients. Am J Clin Nutr 2005; 81: 543–554
    1. Navaneethan SD, Kirwan JP, Arrigain S. et al. Adiposity measures, lean body mass, physical activity and mortality: NHANES 1999–2004. BMC Nephrol 2014; 15: 108.
    1. Levey AS, Stevens LA, Schmid CH. et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604–612
    1. James PA, Oparil S, Carter BL. et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311: 507–520
    1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143–3421
    1. Charlson M, Szatrowski TP, Peterson J. et al. Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47: 1245–1251
    1. Rosenberger J, Kissova V, Majernikova M. et al. Body composition monitor assessing malnutrition in the hemodialysis population independently predicts mortality. J Ren Nutr 2014; 24: 172–176
    1. Kalantar-Zadeh K,, Abbott KC, Salahudeen AK. et al. Survival advantages of obesity in dialysis patients. Am J Clin Nutr 2005; 81: 543–54
    1. Marcelli D, Usvyat LA, Kotanko P. et al. Body composition and survival in dialysis patients: results from an international cohort study. Clin J Am Soc Nephrol 2015; 10: 1192–1200

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する